Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

VERNALIS PLC (VER)

3
Delayed Quote. Delayed London Stock Exchange - 05/01 11:35:00 am
59.5 GBp   +16.10%
05/01 VERNALIS : Says US Regulator Approves New Drug Application For Tuzis..
05/01 VERNALIS : FDA approves NDA for Tuzistra XR
05/01 VERNALIS : and Tris Pharma receive FDA approval of NDA for Tuzistra&..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Vernalis plc
Researches and develops pharmaceutical products

Vernalis Plc is a research and development stage pharmaceutical company.

The company provides pharmaceutical products for a range of medical disorders.

It focuses on de novo fragment and structure based drug discovery and pre clinical and clinical development.

The group has one marketed product, frovatriptan, for the acute treatment of migraines, as well as eight programmes in its NCE development pipeline.

The company was founded by Keith G. McCullagh in 1986 and is headquartered in Wokingham, the United Kingdom.
Sales per Businesses
20122013Delta
GBP (in Million)%GBP (in Million)%
Pharmaceuticals14.62100%14.08100% -3.78%
Sales per Regions
20122013Delta
GBP (in Million)%GBP (in Million)%
Rest of Europe12.7487.2%10.6475.5% -19.78%
North America1.8212.4%3.0521.7% +40.41%
Rest of the World0.0340.2%0.3742.7% +90.91%
United Kingdom0.0210.1%0.0200.1% -5%
Managers
NameAgeSinceTitle
Ian Garland492008Chief Executive Officer & Executive Director
Peter John Fellner, PhD702003Non-Executive Chairman
David MacKney472009Chief Financial Officer & Executive Director
Mike Wood-2004Research Director
Pascal Borderies-2014Senior Vice President-Medical Affairs
Carol C. Ferguson682003Senior Independent Non-Executive Director
Nigel Sheail492011Independent Non-Executive Director
Kevin Kissane592010Secretary & General Counsel
Nerida Scott, PhD-2002Director-Business Development & Licensing
Shareholders
NameShares%
Invesco Asset Management Ltd. 160,207,135 36.2%
Woodford Investment Management LLP 92,589,127 20.9%
Legal & General Investment Management Ltd. 43,856,399 9.92%
GAM London Ltd. 43,233,153 9.77%
Aviva Investors Global Services Ltd. 27,702,188 6.26%
JPMorgan Asset Management (UK) Ltd. 13,223,731 2.99%
River & Mercantile Asset Management LLP 11,486,274 2.60%
Rothschild Bank AG 11,129,000 2.52%
Majedie Asset Management Ltd. 8,748,461 1.98%
J.O. Hambro Capital Management Ltd. 7,600,000 1.72%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
PHARMACYCLICS, IN..
INCYTE CORPORATIO..
ALNYLAM PHARMACEU..
ALKERMES PLC
CELLTRION, INC.
QUINTILES TRANSNA..
UNITED THERAPEUTI..
ISIS PHARMACEUTIC..
QIAGEN NV
PUMA BIOTECHNOLOG..
-
SEATTLE GENETICS,..
INTREXON CORP
ICON PLC
SYNAGEVA BIOPHARM..
BIO-TECHNE CORP
ACADIA PHARMACEUT..
PAREXEL INTERNATI..
BB BIOTECH AG
CHARLES RIVER LAB..
WUXI PHARMATECH (..
Sector Biotechnology & Medical Research
Vernalis plc : Connections
Chartered Accountants Compensation Scheme Ltd.
The Institute of Chartered Accountants of Scotland
Bayer HealthCare
Company contact information
Vernalis Plc
100 Berkshire Place
Wharfedale Road
Winnersh, Berkshire RG41 5RD

Phone : +44.118.938.0000
Fax : +44.118.938.0001
Web : www.vernalis.com
© 2015 People , Fundamentals and Ownership   
Dynamic quotes  
ON
| OFF